AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3550149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous self-injection of phentolamine and papaverine
Number of subjects: 30
Study 3550149 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 30882529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-level cognitive tasks (serial subtract 3)
Number of subjects: 11
Study 30882529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-level cognitive tasks (serial subtract 7)
Number of subjects: 11
Study 30882529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid visual input processing primary reaction time
Number of subjects: 11
Study 28720080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy (NRT; nicotine patch) for 5 weeks
Number of subjects: 924
Study 28720080 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 924
Study 26325640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine HCl
Number of subjects: 50
Study 26325640 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 50
Study 23635012 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of dialysate sodium concentration from 138 to 135 mEq/L (Group A)
Number of subjects: 52
Study 23635012 — intervention group
Group type: COMPARATOR
Intervention: No reduction of dialysate sodium concentration (Group B)
Number of subjects: 52
Study 20708269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal clindamycin and dexamethasone (IVCD)
Number of subjects: 68
Study 18482012 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion extract gel treatment
Number of subjects: 60
Study 18482012 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study 17058225 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg daily
Number of subjects: 52
Study 17058225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg daily
Number of subjects: 52
Study 17058225 — intervention group
Group type: COMPARATOR
Intervention: Both ADV and TDF
Number of subjects: 52
Study 12221213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically hydrolyzed isoflavone drink (1 mg total isoflavones/kg body)
Number of subjects: 6
Study 12221213 — intervention group
Group type: COMPARATOR
Intervention: Non-hydrolyzed isoflavone drink (1 mg total isoflavones/kg body)
Number of subjects: 6
Study 9475650 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet Suit (WS)
Number of subjects: 5
Study 9475650 — intervention group
Group type: COMPARATOR
Intervention: Swimming Suit (SS)
Number of subjects: 5
Study 7620688 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 5 mg/24 hours for 2 weeks, titrated to 10 mg/24 hours for 4 weeks if needed
Number of subjects: 2456
Study 7620688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitrates (previous treatment)
Number of subjects: 2456
Study 7620688 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous treatment with oral nitrates)
Number of subjects: 2456
Study 2239903 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 176
Study 2239903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 2239903 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group and Control group combined
Number of subjects: 176
Study 364393 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (2 mg/kg intravenously)
Number of subjects: 12
Study 364393 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose water in 0.225% sodium chloride (control group)
Number of subjects: 12
Study 31537171 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test (ANT) under symptom provocation conditions
Number of subjects: 22
Study 31537171 — intervention group
Group type: COMPARATOR
Intervention: Non-clinical controls
Number of subjects: 22
Study 28616772 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke_less (CBT program: four weekly group sessions and two telephone calls over 5 weeks, n = 51)
Number of subjects: 155
Study 28616772 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (one 15-minute counseling session, n = 49)
Number of subjects: 155
Study 28616772 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no intervention during the study, n = 55)
Number of subjects: 155
Study 27899150 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials reporting treatment effect estimate and/or p-value
Number of subjects: 2823
Study 27899150 — intervention group
Group type: COMPARATOR
Intervention: Trials with no treatment effect estimate or p-value posted
Number of subjects: 2823
Study 24528600 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical and leisure activity programme
Number of subjects: 52
Study 24528600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 22633344 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 105
Study 22633344 — intervention group
Group type: COMPARATOR
Intervention: Patching
Number of subjects: 105
Study 20729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Add on ADV to ongoing LAM (Group 2)
Number of subjects: 99
Study 20729619 — intervention group
Group type: EXPERIMENTAL
Intervention: Add on LAM to ADV monotherapy (Group 3)
Number of subjects: 99
Study 20729619 — intervention group
Group type: COMPARATOR
Intervention: Switch to ADV monotherapy (Group 1)
Number of subjects: 99
Study 17708584 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 939
Study 17708584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study 17039651 — intervention group
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Number of subjects: 38546
Study 15344896 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of intracranial hemorrhage resulting from bleeding disorders
Number of subjects: 0
Study 10476589 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (bolus and 12 hour infusion) with weight-adjusted low-dose heparin
Number of subjects: 106
Study 10476589 — intervention group
Group type: COMPARATOR
Intervention: Weight-adjusted heparin alone
Number of subjects: 106
Study 8758450 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine detoxification (10 days program)
Number of subjects: 100
Study 8758450 — intervention group
Group type: COMPARATOR
Intervention: Methadone detoxification (10 days program)
Number of subjects: 100
Study 8758450 — intervention group
Group type: COMPARATOR
Intervention: Clonidine treatment (10 days program)
Number of subjects: 100
Study 1951162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (WHO recommended dose)
Number of subjects: 60
Study 1951162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6112411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular orgotein (4 mg/week for 6 weeks)
Number of subjects: 30
Study 6112411 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular aspirin (4 mg/week for 6 weeks)
Number of subjects: 30
Study 6112411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular orgotein
Number of subjects: 30
Study 31397768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 160
Study 31397768 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 160
Study 31397768 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent exercisers
Number of subjects: 160
Study 31397768 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent exercisers
Number of subjects: 160
Study 15887359 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training (CB)
Number of subjects: 141
Study 15887359 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led training (IL)
Number of subjects: 141
Study 15887359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 29454587 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutations
Number of subjects: 313
Study 29454587 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 313
Study 29454587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mutations)
Number of subjects: 313
Study 26983794 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative educational program (monitoring of arm dysfunction, exercises, massage, and lifestyle adjustments) over 12 months
Number of subjects: 64
Study 26983794 — intervention group
Group type: COMPARATOR
Intervention: Control group received written information about shoulder exercise before surgery
Number of subjects: 64
Study 24134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous 1500 U/kg rEPO at day-1
Number of subjects: 45
Study 24134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia for 72 hours
Number of subjects: 45
Study 24134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 45
Study 24134405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 24134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 45
Study 24134405 — intervention group
Group type: EXPERIMENTAL
Intervention: rEPO
Number of subjects: 45
Study 22240377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 2 × 60 min·wk(‐1) treadmill walking
Number of subjects: 0
Study 22240377 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 4 × 30 min·wk(‐1) treadmill walking
Number of subjects: 0
Study 20190068 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Topics Overview (HTO) available without direct links to answers
Number of subjects: 48
Study 20190068 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Topics Overview (HTO) available with direct links to answers
Number of subjects: 48
Study 20190068 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Topics Overview (HTO) not available
Number of subjects: 48
Study 20190068 — intervention group
Group type: COMPARATOR
Intervention: Health Topics Overview (HTO) available
Number of subjects: 48
Study 18416955 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct research project (Tromsø Mammography and Breast Cancer study)
Number of subjects: 650
Study 18416955 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no adjunct research project)
Number of subjects: 650
Study 15824048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 350 U
Number of subjects: 50
Study 15824048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 500 U
Number of subjects: 50
Study 15824048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 1000 U
Number of subjects: 50
Study 15824048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12422330 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point bending lumbar extension traction, provided in-office 3 to 4 times a week for 12+/−4 weeks; traction duration started at 3 minutes and increased to a maximum of 20 minutes.
Number of subjects: 48
Study 12422330 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point bending lumbar extension traction
Number of subjects: 48
Study 12422330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 10815082 — intervention group
Group type: EXPERIMENTAL
Intervention: ancrod
Number of subjects: 500
Study 10815082 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 500
Study 8992090 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser flare meter FM‐500 (Kowa, diode laser, 670 nm)
Number of subjects: 31
Study 8992090 — intervention group
Group type: COMPARATOR
Intervention: Laser flare-cell meter FC‐1000 (Kowa, He‐Ne laser, 632.8 nm)
Number of subjects: 31
Study 1670591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxyinosine (ddl) administered orally in three divided doses totaling 60, 120, 180, 360, or 540 mg per square meter of body-surface area per day for 24 weeks
Number of subjects: 43
Study 1670591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxyinosine (ddl) administered orally
Number of subjects: 43
Study 6606153 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 30
Study 6606153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6606153 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 30
Study 30898654 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) training with motor imagery
Number of subjects: 0
Study 30898654 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback (Control)
Number of subjects: 0
Study 28019071 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 0.75 mg/d
Number of subjects: 0
Study 28019071 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 1.25 mg/d
Number of subjects: 0
Study 28019071 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 27071986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 34
Study 27071986 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 34
Study 27071986 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Fidaxomicin and Vancomycin
Number of subjects: 34
Study 24612248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-enriched virgin olive oil (300 ppm) (1.5 mL three times a day)
Number of subjects: 60
Study 24612248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 mL three times a day)
Number of subjects: 60
Study 24612248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-enriched virgin olive oil (300 ppm)
Number of subjects: 60
Study 24612248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21993020 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Training Group (MTG, 07:00-08:00 hours, n = 10)
Number of subjects: 30
Study 21993020 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Training Group (ETG, 17:00-18:00 hours, n = 10)
Number of subjects: 30
Study 21993020 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 10)
Number of subjects: 30
Study 20380653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg qd
Number of subjects: 24
Study 20380653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18166880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional strategy (systematic mailing of the test kit to all non-responders)
Number of subjects: 10930
Study 18166880 — intervention group
Group type: COMPARATOR
Intervention: Experimental strategy (mailing the test kit only to non-responders who requested it after receiving a recall letter)
Number of subjects: 10930
Study 18166880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional strategy
Number of subjects: 10930
Study 18166880 — intervention group
Group type: COMPARATOR
Intervention: Experimental strategy
Number of subjects: 10930
Study 15643227 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled release (3.75 mg once daily)
Number of subjects: 129
Study 15643227 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled release (7.5 mg once daily)
Number of subjects: 129
Study 15643227 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled release (15 mg once daily)
Number of subjects: 129
Study 15643227 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin immediate-release (5 mg 3 times daily)
Number of subjects: 129
Study 15643227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 12297120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (Caelyx)
Number of subjects: 474
Study 12297120 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 474
Study 10594399 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM b.d. (omeprazole 20 mg b.d., amoxycillin 1000 mg b.d., metronidazole 800 mg b.d.)
Number of subjects: 255
Study 10594399 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM t.d.s. (omeprazole 40 mg o.d., amoxycillin 500 mg t.d.s., metronidazole 400 mg t.d.s.)
Number of subjects: 255
Study 8214416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg of thyrotropin-releasing hormone (TRH) IV
Number of subjects: 18
Study 8214416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3116661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (200 ml vegetable oil)
Number of subjects: 8
Study 3116661 — intervention group
Group type: COMPARATOR
Intervention: Control (200 ml glucose)
Number of subjects: 8
Study 28442236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low omega-3 index (lowest quartile)
Number of subjects: 1449
Study 28442236 — intervention group
Group type: EXPERIMENTAL
Intervention: High omega-3 index (three upper quartiles)
Number of subjects: 1449
Study 28442236 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted omega-3 index
Number of subjects: 1449
Study 27456376 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List (DT&PL)
Number of subjects: 0
Study 24206869 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAX report
Number of subjects: 60
Study 24206869 — intervention group
Group type: COMPARATOR
Intervention: CAROC report
Number of subjects: 60
Study 22642607 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser therapy (660 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Number of subjects: 114
Study 22642607 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser therapy (780 nm) applied at three points directly on the episiotomy after suturing in a single session between 6-56 hours postpartum.
Number of subjects: 114
Study 22642607 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent all laser procedures excluding the emission of irradiation.
Number of subjects: 114
Study 19960200 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day supplementation with a whey-based cysteine donor
Number of subjects: 27
Study 19960200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 27
Study 18843428 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time hand positioning splint
Number of subjects: 50
Study 18843428 — intervention group
Group type: COMPARATOR
Intervention: Control group (splint used only during evaluations)
Number of subjects: 50
Study 16009884 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (44-microg three times weekly)
Number of subjects: 368
Study 16009884 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (22-microg three times weekly)
Number of subjects: 368
Study 16009884 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 368
Study 11835748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 77
Study 11835748 — intervention group
Group type: COMPARATOR
Intervention: Surgical intraventricular drainage
Number of subjects: 77
Study 10069556 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 49
Study 10069556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10069556 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone and Placebo (combined analysis)
Number of subjects: 49
Study 8674225 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight pulse oximetry in children undergoing adenotonsillectomy
Number of subjects: 255
Study 8674225 — intervention group
Group type: COMPARATOR
Intervention: Overnight pulse oximetry in normal children
Number of subjects: 255
Study 8674225 — intervention group
Group type: EXPERIMENTAL
Intervention: Children undergoing adenotonsillectomy
Number of subjects: 255
Study 8674225 — intervention group
Group type: COMPARATOR
Intervention: Normal population
Number of subjects: 255
Study 1872023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A (adsorbed tetanus toxoid, 69 IIU/0.5 ml)
Number of subjects: 0
Study 1872023 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B (adsorbed tetanus toxoid, 212 IIU/0.5 ml)
Number of subjects: 0
Study 6633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I with platinum and bleomycin
Number of subjects: 49
Study 6633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen II with bleomycin, cyclophosphamide, methotrexate and 5‐fluorouracil
Number of subjects: 49
Study 6633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality approach (including radiotherapy or surgery)
Number of subjects: 49
Study 6633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 49
Study 6633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 49
Study 31701429 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG mouthwash (starting at 440 μmol/L, three times a day, maximum tolerated dose 2200 μmol/L)
Number of subjects: 20
Study 31701429 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG mouthwash
Number of subjects: 20
Study 31475297 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic surgery
Number of subjects: 13722
Study 31475297 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 13722
Study 27770628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone 30 mg perioperatively
Number of subjects: 20
Study 27770628 — intervention group
Group type: COMPARATOR
Intervention: No Dexamethasone (controls)
Number of subjects: 20
Study 25937184 — intervention group
Group type: EXPERIMENTAL
Intervention: Steeper decline in eGFR in women
Number of subjects: 6999
Study 25937184 — intervention group
Group type: EXPERIMENTAL
Intervention: Steeper decline in eGFR in men
Number of subjects: 6999
Study 25937184 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining kidney function in women accounting for competing risk of death
Number of subjects: 6999
Study 25937184 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining kidney function in men accounting for competing risk of death
Number of subjects: 6999
Study 25109511 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (tianeptine sodium 12.5 mg)
Number of subjects: 40